Lenalidomide is used to treat anemia (low red blood cells) in patients with a specific type of myelodysplastic syndrome (MDS). Patients with MDS might have very low red blood cell counts and need blood transfusions.
Lenalidomide is also used together with dexamethasone to treat multiple myeloma (plasma cell cancer). It is also used as maintenance treatment in patients suffering from multiple myeloma after an autologous hematopoietic stem cell transplant (stem cell transplant that uses your own stem cells).
Lenalidomide is also used for the treatment of mantle cell lymphoma (MCL) in patients who have been treated previously with bortezomib and one additional medicine that did not work well.
Lenalidomide is also used in combination with rituximab to treat previously treated follicular lymphoma (FL) and marginal zone lymphoma (MZL).
This medicine is available only under a restricted distribution program also known as the Lenalidomide REMS (Risk Evaluation and Mitigation Strategy) program.
The product is available in the following dosing forms: